気管支拡張薬市場：薬剤クラス別、投与経路別、疾患別、エンドユーザー別-2025-2030年の世界予測

気管支拡張薬市場は、2023年に183億7,000万米ドルと評価され、2024年には192億米ドルに達すると予測され、CAGR 5.98%で成長し、2030年には275億9,000万米ドルに達すると予測されています。

市場セグメンテーションは、広範な呼吸器治療薬市場において重要なセグメントであり、主に肺の空気の通り道を弛緩・拡張し、気流を改善して喘息やCOPD（慢性閉塞性肺疾患）などの症状を緩和するために使用されます。気管支拡張薬の必要性は、呼吸器疾患の世界の有病率の増加、特に環境汚染、喫煙、労働災害の発生率の上昇に起因しています。気管支拡張薬の用途は、吸入器、ネブライザー、経口薬など様々な投与方法に及び、急性および慢性の治療ニーズに対応しています。これらの薬剤は、病院での緊急治療から、長期的な状態管理が必要な患者による日常的な在宅使用まで、多様な最終用途に対応しています。市場成長は、ドラッグデリバリーシステムの技術的進歩、認知度の向上、個々の患者プロファイルに合わせた個別化医療への需要に強く影響されています。さらに、発展途上地域におけるヘルスケア・インフラの台頭は、潜在的な拡大機会をもたらします。主な成長機会は、副作用を低減し効率を改善するための新しい製剤の研究開発、呼吸器疾患のより良いモニタリングと管理のためのデジタルヘルスプラットフォームの活用にあります。しかし、市場に課題がないわけではなく、厳しい規制要件、高い開発コスト、長期使用に伴う潜在的な副作用が大きな障壁となっています。生物学的療法など競合する治療法も市場シェアを脅かしています。新規化合物の探索、患者のアドヒアランス技術の改善、予測的ヘルスケア提供のための人工知能の統合など、革新的な道が存在します。気管支拡張薬市場の性質は非常にダイナミックで、製品パイプラインの強化や戦略的な地域情勢別拡大を目的としたM&Aの継続が顕著であり、規制状況や消費者の需要に継続的に適応する必要があります。

市場力学：急速に進化する気管支拡張薬市場の主要市場インサイトを公開

気管支拡張薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の呼吸器疾患の有病率の上昇
  • 喘息および嚢胞性線維症の呼吸器疾患に対する意識の高まり
• 市場抑制要因
  • 慢性気管支炎の治療に必要な莫大な支出
• 市場機会
  • 新薬開発のための活発な研究活動気管支拡張薬
  • 慢性気管支炎治療のための臨床試験の増加
• 市場の課題
  • 気管支拡張薬の消費に伴う副作用

ポーターの5つの力：気管支拡張薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、気管支拡張薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：気管支拡張薬市場における外部からの影響の把握

外部マクロ環境要因は、気管支拡張薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析気管支拡張薬市場における競合情勢の把握

気管支拡張薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス気管支拡張薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、気管支拡張薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨気管支拡張薬市場における成功への道筋を描く

気管支拡張薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で呼吸器疾患の罹患率が上昇
    • 喘息や嚢胞性線維症などの呼吸器疾患に関する意識の高まり
  • 抑制要因
    • 慢性気管支炎の治療には莫大な費用が必要
  • 機会
    • 新規開発に向けた強力な調査活動気管支拡張薬
    • 慢性気管支炎の治療に関する臨床試験の増加
  • 課題
    • 気管支拡張薬の摂取に伴う副作用
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 気管支拡張薬市場薬剤クラス別

• 抗コリン剤気管支拡張薬
• ベータアドレナリン気管支拡張薬
• キサンチン誘導体

第7章 気管支拡張薬市場：投与経路別

• 注射可能
• 鼻腔
• オーラル

第8章 気管支拡張薬市場：疾患別

• 喘息
• 慢性閉塞性肺疾患

第9章 気管支拡張薬市場：エンドユーザー別

• 病院
• 専門クリニック

第10章 南北アメリカの気管支拡張薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の気管支拡張薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの気管支拡張薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AdvaCare Pharma
• AMGIS Lifescience Ltd.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc.
• Cipla Limited
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Limited
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Mylan Inc. by Viatris Inc.
• Nephron Pharmaceuticals Corporation
• Novartis AG
• Perrigo Company PLC
• Pfizer Inc.
• Prasco Laboratories
• Ralington Pharma LLP
• Siemens Healthcare GmbH
• Steris Healthcare Pvt. Ltd.
• Sun Pharmaceutical Industries Limited
• Teva Pharmaceutical Industries Ltd.
• Thermo Fisher Scientific Inc.
• Vectura Group PLC
• Zydus Group

LIST OF FIGURES

• FIGURE 1. BRONCHODILATORS MARKET RESEARCH PROCESS
• FIGURE 2. BRONCHODILATORS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BRONCHODILATORS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BRONCHODILATORS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BRONCHODILATORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BRONCHODILATORS MARKET DYNAMICS
• TABLE 7. GLOBAL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BRONCHODILATORS MARKET SIZE, BY ANTICHOLINERGIC BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BRONCHODILATORS MARKET SIZE, BY BETA-ADRENERGIC BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BRONCHODILATORS MARKET SIZE, BY XANTHINE DERIVATIVE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BRONCHODILATORS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BRONCHODILATORS MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BRONCHODILATORS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BRONCHODILATORS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BRONCHODILATORS MARKET SIZE, BY COPD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BRONCHODILATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BRONCHODILATORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 34. CANADA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CANADA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES BRONCHODILATORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 56. CHINA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. CHINA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 60. INDIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 61. INDIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA BRONCHODILATORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 129. ITALY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. ITALY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. POLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 146. POLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 149. QATAR BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 150. QATAR BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM BRONCHODILATORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 189. BRONCHODILATORS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 190. BRONCHODILATORS MARKET, FPNV POSITIONING MATRIX, 2023

The Bronchodilators Market was valued at USD 18.37 billion in 2023, expected to reach USD 19.20 billion in 2024, and is projected to grow at a CAGR of 5.98%, to USD 27.59 billion by 2030.

Bronchodilators represent a critical segment within the broader respiratory therapeutics market, primarily used to relax and expand the air passages of the lungs, improving airflow and alleviating symptoms in conditions like asthma and COPD (Chronic Obstructive Pulmonary Disease). The necessity for bronchodilators stems from the increasing prevalence of respiratory disorders globally, particularly with the rising incidence of environmental pollution, smoking, and occupational hazards. The application of bronchodilators spans across various administration methods, including inhalers, nebulizers, and oral medications, catering to both acute and chronic therapeutic needs. These medications serve a diverse end-use scope, extending from emergency hospital care to routine home use by patients needing long-term management of their conditions. Market growth is strongly influenced by technological advancements in drug delivery systems, increased awareness, and demand for personalized medicine tailored to individual patient profiles. Additionally, rising healthcare infrastructure in developing regions presents a potential expansion opportunity. Key growth opportunities lie in the research and development of new formulations to reduce side effects and improve efficiency, as well as the exploitation of digital health platforms for better monitoring and management of respiratory conditions. However, the market is not without its challenges; stringent regulatory requirements, high development costs, and potential side effects associated with long-term use pose significant barriers. Competing treatment modalities, such as biological therapies, also threaten market share. Innovative avenues exist in the exploration of novel compounds, improvement of patient adherence technologies, and the integration of artificial intelligence for predictive healthcare delivery. The nature of the bronchodilator market is highly dynamic, marked by ongoing mergers and acquisitions aimed at product pipeline enhancement and strategic geographic expansion, necessitating continuous adaptation to regulatory landscapes and consumer demand.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bronchodilators Market

The Bronchodilators Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of respiratory disorders worldwide
  • Growing awareness about asthma and cystic fibrosis respiratory disorders
• Market Restraints
  • Huge expenditure required for treating chronic bronchitis
• Market Opportunities
  • Robust research activities to develop noval bronchodilators
  • Increasing number of clinical trials to treat chronic bronchitis
• Market Challenges
  • Side effects associated with consumption of bronchodilators

Porter's Five Forces: A Strategic Tool for Navigating the Bronchodilators Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bronchodilators Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bronchodilators Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bronchodilators Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bronchodilators Market

A detailed market share analysis in the Bronchodilators Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bronchodilators Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bronchodilators Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bronchodilators Market

A strategic analysis of the Bronchodilators Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bronchodilators Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, AMGIS Lifescience Ltd., AstraZeneca PLC, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Cipla Limited, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Mylan Inc. by Viatris Inc., Nephron Pharmaceuticals Corporation, Novartis AG, Perrigo Company PLC, Pfizer Inc., Prasco Laboratories, Ralington Pharma LLP, Siemens Healthcare GmbH, Steris Healthcare Pvt. Ltd., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Vectura Group PLC, and Zydus Group.

Market Segmentation & Coverage

This research report categorizes the Bronchodilators Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Anticholinergic Bronchodilators, Beta-Adrenergic Bronchodilators, and Xanthine Derivative.
• Based on Route of Administration, market is studied across Injectable, Nasal, and Oral.
• Based on Disease, market is studied across Asthma and COPD.
• Based on End-users, market is studied across Hospitals and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of respiratory disorders worldwide
    • 5.1.1.2. Growing awareness about asthma and cystic fibrosis respiratory disorders
  • 5.1.2. Restraints
    • 5.1.2.1. Huge expenditure required for treating chronic bronchitis
  • 5.1.3. Opportunities
    • 5.1.3.1. Robust research activities to develop noval bronchodilators
    • 5.1.3.2. Increasing number of clinical trials to treat chronic bronchitis
  • 5.1.4. Challenges
    • 5.1.4.1. Side effects associated with consumption of bronchodilators
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Bronchodilators Market, by Drug Class

• 6.1. Introduction
• 6.2. Anticholinergic Bronchodilators
• 6.3. Beta-Adrenergic Bronchodilators
• 6.4. Xanthine Derivative

7. Bronchodilators Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Nasal
• 7.4. Oral

8. Bronchodilators Market, by Disease

• 8.1. Introduction
• 8.2. Asthma
• 8.3. COPD

9. Bronchodilators Market, by End-users

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Specialty Clinics

10. Americas Bronchodilators Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Bronchodilators Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Bronchodilators Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AdvaCare Pharma
• 2. AMGIS Lifescience Ltd.
• 3. AstraZeneca PLC
• 4. Boehringer Ingelheim International GmbH
• 5. Cambrex Corporation
• 6. Catalent, Inc.
• 7. Cipla Limited
• 8. GlaxoSmithKline PLC
• 9. Glenmark Pharmaceuticals Limited
• 10. Hikma Pharmaceuticals PLC
• 11. Lupin Limited
• 12. Mylan Inc. by Viatris Inc.
• 13. Nephron Pharmaceuticals Corporation
• 14. Novartis AG
• 15. Perrigo Company PLC
• 16. Pfizer Inc.
• 17. Prasco Laboratories
• 18. Ralington Pharma LLP
• 19. Siemens Healthcare GmbH
• 20. Steris Healthcare Pvt. Ltd.
• 21. Sun Pharmaceutical Industries Limited
• 22. Teva Pharmaceutical Industries Ltd.
• 23. Thermo Fisher Scientific Inc.
• 24. Vectura Group PLC
• 25. Zydus Group